Wednesday, February 25, 2026
ISSN 2765-8767
  • Survey
  • Podcast
  • Write for Us
  • My Account
  • Log In
Daily Remedy
  • Home
  • Articles
  • Podcasts
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025

    The cost structure of hospitals nearly doubles

    July 1, 2025
    Navigating the Medical Licensing Maze

    The Fight Against Healthcare Fraud: Dr. Rafai’s Story

    April 8, 2025
  • Surveys

    Surveys

    How Confident Are You in RFK Jr.’s Health Leadership?

    How Confident Are You in RFK Jr.’s Health Leadership?

    February 16, 2026
    AI in Healthcare Decision-Making

    AI in Healthcare Decision-Making

    February 1, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
  • Home
  • Articles
  • Podcasts
    Debunking Myths About GLP-1 Medications

    Debunking Myths About GLP-1 Medications

    February 16, 2026
    The Future of LLMs in Healthcare

    The Future of LLMs in Healthcare

    January 26, 2026
    The Future of Healthcare Consumerism

    The Future of Healthcare Consumerism

    January 22, 2026
    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    Your Body, Your Health Care: A Conversation with Dr. Jeffrey Singer

    July 1, 2025

    The cost structure of hospitals nearly doubles

    July 1, 2025
    Navigating the Medical Licensing Maze

    The Fight Against Healthcare Fraud: Dr. Rafai’s Story

    April 8, 2025
  • Surveys

    Surveys

    How Confident Are You in RFK Jr.’s Health Leadership?

    How Confident Are You in RFK Jr.’s Health Leadership?

    February 16, 2026
    AI in Healthcare Decision-Making

    AI in Healthcare Decision-Making

    February 1, 2026

    Survey Results

    Can you tell when your provider does not trust you?

    Can you tell when your provider does not trust you?

    January 18, 2026
    Do you believe national polls on health issues are accurate

    National health polls: trust in healthcare system accuracy?

    May 8, 2024
    Which health policy issues matter the most to Republican voters in the primaries?

    Which health policy issues matter the most to Republican voters in the primaries?

    May 14, 2024
    How strongly do you believe that you can tell when your provider does not trust you?

    How strongly do you believe that you can tell when your provider does not trust you?

    May 7, 2024
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner
No Result
View All Result
Daily Remedy
No Result
View All Result
Home Perspectives

A Comment on the CDC’s Commentary

Daily Remedy by Daily Remedy
April 10, 2022
in Perspectives
0
A Comment on the CDC's Commentary

Words are funny. They are a series of letters that in turn are a series of lines and curves. But when combined, they create a lasting impression that forms a mental picture.

When you analyze the comments in response to the draft CDC guidelines on prescribing opioids for chronic pain, you get a full picture of guidelines, both in what is written and what is implied. The comments show how the guidelines will be interpreted and reveal the perspectives of those who will be most affected by those interpretations.

In that sense, the words in the comments may be more important than the words in the guidelines themselves. On April 4th, a week before the deadline to post additional comments, a well-respected patient advocate, Dr. Richard Lawhern, compiled a list of words that were trending in the comments.

They revealed much about how the public sees the guidelines. The word “taper” appears 359 times and the word “forced” appears 571 times. Both are among the most commonly seen words and together form a stark juxtaposition, because it discloses a pervasive sentiment that the tapering guidelines will be used to force patients off opioids.

Yet, the guidelines repeatedly state that patients on long-term opioids should not be abandoned, or that patients should never be tapered off opioids without a legitimate medical concern. That may be what the authors of the guidelines write, but that is not what those commenting believe. In fact, the comments reveal who the public believes will actually implement the guidelines.

The word “law” appears 471 times and “DEA” appears 426 times. This is in contrast to the words “education” and “evidence” and “ethic[al]”, which appear 189, 164, and 39 times, respectively. Few truly believe the guidelines will be used as evidence to guide clinical decisions, or as a clinical tool to assist in clinical decision-making. Most know the guidelines will be used just like the 2016 guidelines – as a means for law enforcement to investigate and indict patients and providers.

That is why the word “harm” appears 452 times, nearly as frequently as “law” and “DEA”. Yet, no law enforcement agency was involved in the guidelines, let alone the DEA, but the specter of legal ramifications looms large in the comments – revealing a lingering disconnect between the guidelines’ intentions and its effective implementation that has not been addressed in the 2022 revisions.

Since the 2016 guidelines were enacted, patients have been forced to wean below a certain dose, which is loosely defined as 90 MME (morphine milligram equivalent), a grossly inaccurate way of calculating daily opioid intake. The 2022 guidelines have removed any mentioning of 90 MME, but the word “50” appears 302 times, mostly with the word, “MME”.

It seems odd that the authors would make such a gaffe, particularly since they admitted that placing a fixed opioid quantity in the guidelines can easily lead to misapplications of that quantity as a perceived upper limit. But that is just one of the many concerns expressed about the authors in the comments.

In 2016, there were significant concerns about the authors’ financial motivations and their conflicts of interest. These concerns remain in 2022, and can be seen in many of the comments. The word “redacted” appears 583 times in the comments, the fifth most common word, which is used when describing the CDC’s efforts to hide or avoid disclosing the names of specific authors and their conflicts of interest.

Those commenting as well versed in the world of opioids and chronic pain. They know that the guidelines are developed by a small minority of physicians whose names appear over and over in court testimonies and health department policies. Names like Dr. Andrew Kolodny or Dr. Roger Chou appear as expert witnesses for federal prosecutors and as policy makers on opioid guidelines for multiple federal agencies.

It does not take great leaps in logic to see how those who write opioid prescribing policies, who then also serve as expert witnesses in legal cases, would use the guidelines as legal evidence when taking the stand. Those commenting are wise to the conflicts of interest, whether they are acknowledged by the CDC.

The words in the comments tell it all and reveal everything you need to know about how the guidelines will be implemented.

Words are funny like that.

 

As of April 4th, 2022, Dr. Richard Lawhern counted the following terms trending in the CDC comments:

 

“Redacted” occurs 583 times

“Chronic” occurs 1994 times

“Doctor” or “Doctors” appears 1682 times

“Addict” or “addiction” occurs 900 times

“Suicide” appears 625 times.

“Law” occurs 471 times

“Harm” or “harms” occurs 452 times

“DEA” occurs 426 times

“Fentanyl” occurs 391 times

“Street Drugs” occurs 368 times

“Taper” occurs 359 times, often in the context of forced tapers. “Forced” appears 571 times in multiple contexts.

“Damage” occurs 353 times

“Illegal” occurs 323 times

“Pharmacy” occurs 325 times

The number “50” occurs 302 times, often in association with “MME”

“Cancer” occurs 299 times

“Risk” occurs 275 times

“Wrong” or “wrongful” occurs 271 times

“Hospital” occurs 255 times

“Alternative” occurs 256 times

“Retire” or “Retired” occurs 225 times

“Denied” occurs 248 times

“Seeking” occurs 224 times

“Depression” occurs 218 times

“Education” occurs 189 times

“Tylenol” occurs 179 times

“Pharmacist” occurs 168 times

“Evidence” occurs 164 times

“Board” occurs 152 times

“Urine” occurs 151 times

“Training” occurs 150 times (“testing” occurs 368 times)

“Gabapentin” occurs 132 times

“MD” occurs 121 times

“Stimulation” occurs 106 times

“Oxycontin” occurs 104 times

“Surgical” occurs 98 times

“Enforcement” occurs 94 times

“Contract” occurs 88 times

“Epidural” occurs 83 times

“PROP” occurs 73 times

“False” occurs 66 times

“Preferred” occurs 56 times

“CRPS” occurs 49 times

“Hospice” occurs 45 times

“Bias” appears 41 times

“Ethics” or “Ethical” occurs 39 times

“Junk science” appears 35 times

“Voluntary” occurs 35 times while “mandatory” occurs 40 times.

“PDMP” occurs 27 times

ShareTweet
Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Videos

This conversation focuses on debunking myths surrounding GLP-1 medications, particularly the misinformation about their association with pancreatic cancer. The speaker emphasizes the importance of understanding clinical study designs, especially the distinction between observational studies and randomized controlled trials. The discussion highlights the need for patients to critically evaluate the sources of information regarding medication side effects and to empower themselves in their healthcare decisions.

Takeaways
GLP-1 medications are not linked to pancreatic cancer.
Peer-reviewed studies debunk misinformation about GLP-1s.
Anecdotal evidence is not reliable for general conclusions.
Observational studies have limitations in generalizability.
Understanding study design is crucial for evaluating claims.
Symptoms should be discussed in the context of clinical conditions.
Not all side effects reported are relevant to every patient.
Observational studies can provide valuable insights but are context-specific.
Patients should critically assess the relevance of studies to their own experiences.
Engagement in discussions about specific studies can enhance understanding

Chapters
00:00
Debunking GLP-1 Medication Myths
02:56
Understanding Clinical Study Designs
05:54
The Role of Observational Studies in Healthcare
Debunking Myths About GLP-1 Medications
YouTube Video DM9Do_V6_sU
Subscribe

2027 Medicare Advantage & Part D Advance Notice

Clinical Reads

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

by Daily Remedy
February 15, 2026
0

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!

Twitter Updates

Tweets by TheDailyRemedy

Popular

  • A homeowner using his massage chair at home. He's wearing comfortable clothing and using the remote to start his session.

    Common Problems and Solutions With Massage Chairs

    0 shares
    Share 0 Tweet 0
  • The Staffing Equation That Doesn’t Balance

    0 shares
    Share 0 Tweet 0
  • What is the 411 on the New 988 Hotline?

    0 shares
    Share 0 Tweet 0
  • How Clinically Significant is a Healthy Diet?

    0 shares
    Share 0 Tweet 0
  • Healthcare Natural Rights

    0 shares
    Share 0 Tweet 0
  • 628 Followers

Daily Remedy

Daily Remedy offers the best in healthcare information and healthcare editorial content. We take pride in consistently delivering only the highest quality of insight and analysis to ensure our audience is well-informed about current healthcare topics - beyond the traditional headlines.

Daily Remedy website services, content, and products are for informational purposes only. We do not provide medical advice, diagnosis, or treatment. All rights reserved.

Important Links

  • Support Us
  • About Us
  • Contact us
  • Privacy Policy
  • Terms and Conditions

Join Our Newsletter!

  • Survey
  • Podcast
  • About Us
  • Contact us

© 2026 Daily Remedy

No Result
View All Result
  • Home
  • Articles
  • Podcasts
  • Surveys
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Official Learner

© 2026 Daily Remedy